Apjohn Ventures Fund is a new venture capital firm based in Kalamazoo, Michigan established to invest primarily in early stage life sciences companies across the Midwest. The goal of the Fund is to provide investors with superior financial returns by making equity investments in innovative life sciences companies with sustainable and outstanding growth potential.
We take our name, Apjohn, from the original family name of one of our founders. The use of this family name reflects our desire to inspire life sciences entrepreneurs to build pharmaceutical successes much like Dr. William E. Upjohn did at the turn of the last century.
We welcome you to our web site and invite you to learn more about Apjohn Ventures.
FDA Accepts New Drug Application (NDA) to review Midazolam Nasal Spray, an investigational product for the acute treatment of seizure clusters
ProNAi Therapeutics Announces Pricing of Initial Public Offering
BioMarin Doses First Patient in Phase 3 INSPIRE Trial With BMN 701 for the Treatment of
ProNAi Therapeutics Reports Anti-Tumor Activity from Ongoing Phase II Clinical Study of PNT2258, a Novel BCL2-Inhibitor, at ASH Annual Meeting
ProNAi to Present Phase II Clinical Data at ASH for PNT2258, a BCL2 Targeted Drug
BioMarin to Advance BMN-701 for Pompe Disease to Next Phase (2/3) of Development
ProNAi Expands Management Team and Presents Encouraging Phase I Study Results for Lead Cancer Drug at Cancer Meeting
Svelte Medical Systems Announces Final Patient Treated in the DIRECT Drug-Eluting Stent Study
Smarticles Extend Their Reach In ProNAi’s DNAi Approach
CytoPherx Raises $34 Million to Move Into U.S. Clinical Trials
Svelte Medical Systems Offers All-In-One Drug-Eluting Stent Application
BioMarin Acquires ZyStor Therapeutics, Inc.
Upsher-Smith Laboratories Adds ITI-111 (Nasal Midazolam) to CNS Development Pipeline